A comprehensive view of FDA Drug/Device Reviews. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

GSK announces positive results in Phase 2 study showing its investigational tuberculosis medicine GSK3036656 is well-tolerated and shows early effectiveness at a low daily dose for 14 days
Published: November 14, 2022 by U.S. Regulated Equity Markets (Alternative Disclosure) via PUBT
GSK updates prescribing information for the ovarian cancer drug Zejula, limiting use to second-line maintenance therapy only to patients with certain mutation types; change was made at the request of FDA following review of Phase 3 clinical results
Published: November 14, 2022 by PharmaBiz (India)
AstraZeneca and Daiichi Sankyo’s Enhertu injection recommended for approval in the EU as a treatment for certain type of gastric cancer; drug is currently approved in the US
Published: November 14, 2022 by AstraZeneca AB
AstraZeneca’s Imfinzi recommended in the EU for approval as a first-line treatment for unresectable or metastatic biliary tract cancer; treatment is used in combination with chemotherapy
Published: November 14, 2022 by AstraZeneca AB
AstraZeneca and MSD's Lynparza combined with abiraterone and prednisone or prednisolone has been recommended in the EU for approval as a treatment for metastatic castration-resistant prostate cancer
Published: November 14, 2022 by AstraZeneca AB

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count